Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. - Wikidata - wikimedia - TriplyDB

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

http://www.wikidata.org/entity/Q45722783

about

Antiretroviral resistance testing in treatment-naive HIV-infected adults Antiretroviral resistance testing in treatment-naive HIV-infected adults Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings SVARAP and aSVARAP: simple tools for quantitative analysis of nucleotide and amino acid variability and primer selection for clinical microbiology.Use of sequence data generated in the Bayer Tru Gene genotyping assay to recognize and characterize non-subtype-b human immunodeficiency virus type 1 strains Combinatorial selection, inhibition, and antiviral activity of DNA thioaptamers targeting the RNase H domain of HIV-1 reverse transcriptase Magnetic silica extraction for low-viremia human immunodeficiency virus type 1 genotyping Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy Information management to enable personalized medicine: stakeholder roles in building clinical decision support.Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.Modeling-error robustness of a viral-load preconditioning strategy for HIV treatment switching.Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia.TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs.Model for assessment of proficiency of human immunodeficiency virus type 1 sequencing-based genotypic antiretroviral assays Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection.A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA.Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent.Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus Antiretroviral treatment of HIV infected adults Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach.Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection Evolution of drug-resistant viral populations during interruption of antiretroviral therapy The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.

P2860

Q24198919-0E5C4AB9-5F57-475E-98C8-74EA957906CC Q24240372-63EF7243-ADA1-4C7B-8C2C-01767568B3AA Q24243499-82109766-4A75-4240-B69C-87D2ED42B4C5 Q24537285-BC19FA25-A994-421E-AF97-E71C9B25C558 Q27487949-FD08625A-29DF-4FB5-84BA-2D419F9F1232 Q28469116-7D4366C3-BCC9-4692-BC15-01723933E68B Q28471687-7C204098-3B05-4735-A718-B0976713AA05 Q28478154-420649F9-4942-459D-9C1F-850FFB924DC2 Q30810347-34699C5A-3EF0-4B40-ADE1-98632CB40151 Q31009699-A9F056EC-7B97-4A91-A329-22BC4DC80264 Q33220293-B0DDA4D6-4443-4217-8504-CB3F1F656C73 Q33264429-82574FF1-61A9-4135-B985-9CA9DB9BC477 Q33345228-808851AA-2385-4443-A774-9BCAFE3D4DDA Q33378828-A006B016-5A26-45D7-90F9-F2C10D299F3D Q33509401-2FAC474B-CF7D-4C81-A159-98E6DA43F5E2 Q33649563-99D91B6E-39E8-428F-9F95-BE8EFEF0D52D Q33771799-11D74AF0-3119-461A-A36F-E0047F706E41 Q33780566-77935167-0D47-46BC-A0D1-BCF820F7B714 Q33820125-1C4DD355-4FD2-4E86-BAB1-7C3E9AE91082 Q33824827-B7E46193-2918-4081-A7BB-04FA782423BC Q33908838-320B5AB0-7DED-43D6-8058-F5A16E4F18C1 Q33911980-8B98537A-1659-484F-8D2B-F00575955878 Q33938098-E290DB01-9C0D-471F-83F8-51FC0DE14E4B Q34041782-8A6806EE-1BD2-4EF4-8FF6-8774451FC59A Q34041819-C0B0792F-F47C-40EF-8E1A-EF82A5108CE3 Q34042986-ADCF0F44-BCA1-4C1E-9644-635EEDF40438 Q34113502-ACF57E95-175F-4196-A8D7-C6C56A061914 Q34143613-AECC098C-5CF0-4296-A582-A9C6F3980C21 Q34303603-64F73DB6-9BFB-4C28-BEF7-A65C704A8FFB Q34352000-C7F84229-A0BE-44B1-8150-BF83E34109C9 Q34545969-F0172300-1257-469B-B688-A239896C605A Q34693248-F75B82DF-3553-4903-95C9-F23F56478F56 Q34719734-FE83A599-2E6D-4A8A-812F-0597183B3111 Q34777454-25602DBF-0194-400C-BD45-96FBC7041730 Q34781852-A5E856A0-EB9B-46DF-AE86-9CF406D81559 Q34976284-2DFCE3D1-7490-4216-B5E8-FAF8CD568D46 Q35077423-C2691E7A-F20A-4579-ABFA-2ED234602D17 Q35111300-96095D34-5845-46AC-8941-619A4D64825B Q35146353-1B8AB3FF-619B-4EBD-9B38-AD084881FF3B Q35560174-9C823ED0-74C2-479F-B0B0-3290BC7172DA

P2860

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

http://www.wikidata.org/entity/Q45722783

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Antiretroviral drug resistance ...... tional AIDS Society-USA Panel.

@en

Antiretroviral drug resistance ...... tional AIDS Society-USA Panel.

@nl

type

label

Antiretroviral drug resistance ...... tional AIDS Society-USA Panel.

@en

Antiretroviral drug resistance ...... tional AIDS Society-USA Panel.

@nl

prefLabel

Antiretroviral drug resistance ...... tional AIDS Society-USA Panel.

@en

Antiretroviral drug resistance ...... tional AIDS Society-USA Panel.

@nl

P1433

Q45722783-2B6893B3-335D-4C16-B03A-EE412465033F

P1476

Q45722783-D070CF94-CA5D-4615-B739-28F4E3F6CBAD

P2093

Q45722783-07A6C3D7-E568-45FF-83D0-A084296BBA0A

Q45722783-2D4BCA53-DF49-4D24-97C3-24B7438C66C5

Q45722783-34D049C0-0987-4E0E-8D44-33482E56EC64

Q45722783-46DA4BF2-DEF2-43D1-9440-DF807D604836

Q45722783-4F589585-004C-4024-AC56-39BA8CF145B9

Q45722783-A3B68CB2-D27C-448B-9725-D4F6C39E8C56

Q45722783-ABEAEA2A-74E0-44E6-9BDB-DBCECE451F75

Q45722783-DD29077C-97BC-4F48-8225-CA048C0B3AB6

Q45722783-DDC2ED3B-9238-4AD0-9B3D-F70ADB273420

Q45722783-F42CC7C2-FF8F-450A-8C7A-4079602DC2B0

P2860

Q45722783-01BF5369-6799-4ACA-834B-1A3C2DB70799

Q45722783-03F7392D-DEDD-42CC-BAE4-268503E46E97

Q45722783-04BADB13-EFBF-4527-A8F4-889C3B3378E8

Q45722783-068E8767-BECE-4075-88F3-FDB6E1FC06A6

Q45722783-07AD82D2-6EE5-4F5E-8F0F-6E8502F720F7

Q45722783-0A34ADCB-2F35-4794-987D-C6B6CEBE1A11

Q45722783-0C56DEE9-DE13-4EAC-8B64-3C32A3B6033F

Q45722783-0C7EF61A-FDCC-4C43-B76B-E0408570B747

Q45722783-0CEF6BE9-9D30-4AC7-A9DB-416579C53BD6

Q45722783-10D11CB0-4531-45AE-83B3-CD3989D42359

P304

Q45722783-04CEDF9B-491E-462C-9444-E7A30401F9E4

P31

Q45722783-C58F66A3-5F2C-42DE-AB48-F282FD0E52C3

P356

Q45722783-843E5040-4622-41FF-95F4-5BC50EFF2841

P407

Q45722783-539DC1C2-44B8-482C-BA92-0F58129B80A6

P433

Q45722783-31285E3D-FE15-4BE5-B183-BD3B192417AD

P478

Q45722783-E1E7160C-1786-4DFF-A572-DDFFD68D6A3F

P50

Q45722783-C3A93C18-5DB6-4419-9E2B-143C2D99E5FB

Q45722783-DB25C779-DFBF-412E-B102-7F71BD4C2076

P577

Q45722783-62EE139D-A81C-4A0E-A201-03E490A35211

P5875

Q45722783-3144A1EC-7AA6-48D9-9DC4-16836D115F54

P698

Q45722783-BD27E87B-9AF9-4836-BD09-F8041BAB8FAE

P356

P1433

Clinical Infectious Diseases

P1476

Antiretroviral drug resistance ...... tional AIDS Society-USA Panel.

@en

P2093

Brian Conway

http://www.w3.org/2001/XMLSchema#string

Clive Loveday

http://www.w3.org/2001/XMLSchema#string

Daniel R Kuritzkes

http://www.w3.org/2001/XMLSchema#string

Donna M Jacobsen

http://www.w3.org/2001/XMLSchema#string

Douglas D Richman

http://www.w3.org/2001/XMLSchema#string

John W Mellors

http://www.w3.org/2001/XMLSchema#string

Lisa M Demeter

http://www.w3.org/2001/XMLSchema#string

Martin S Hirsch

http://www.w3.org/2001/XMLSchema#string

Richard T D'Aquila

http://www.w3.org/2001/XMLSchema#string

Scott M Hammer

http://www.w3.org/2001/XMLSchema#string

P2860

The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance

3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir

P304

113-128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/375597

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Bonaventura Clotet Sala

Françoise Brun-Vézinet

P577

2003-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10688215

http://www.w3.org/2001/XMLSchema#string

P698

12830416

http://www.w3.org/2001/XMLSchema#string